Development of bifeprunox for maintenance treatment of schizophrenia discontinued
Lundbeck and Solvay have announced that they are discontinuing development of bifeprunox for the maintenance treatment of schizophrenia.
Lundbeck and Solvay have announced that they are discontinuing development of bifeprunox for the maintenance treatment of schizophrenia.
After analyzing results from an interim analysis of pooled data, the companies decided that the efficacy data did not support continued development of this agent for the stabilization of nonacute schizophrenia.
FDA issued a nonapprovable letter for bifeprunox for the acute and maintenance treatment of schizophrenia in August 2007. In its letter, FDA stated that a second study would be needed to support the approval of bifeprunox for the maintenance treatment of schizophrenia. The agency also stated that the efficacy data were not sufficient for the approval of bifeprunox for the acute treatment of schizophrenia.
Novo Nordisk Terminates Collaboration with Hims & Hers
June 23rd 2025The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims & Hers continues to offer these compounded drugs.
Read More
